LTZ Therapeutics: Company Market Research Report
Company Overview
- Name: LTZ Therapeutics
- Mission: Innately Driven to Seek Innovation and Bold Solutions for Patients by rebalancing the immune system and restoring health.
- Founded: General information suggests formation around May 2022 by former Genentech executives.
- Key People:
- Robert Li, PhD - Founder & Chief Executive Officer
- Martin Treder, PhD - Co-founder & Chief Scientific Officer
- Jianhui Zhou, PhD - Co-founder & SVP, Discovery
- Wayne Godfrey, MD, MS - Chief Medical Officer
- Stefan Knackmuss, PhD - VP, Pre-clinical Development
- Vivian Tian, PhD, MBA - VP, Business Development
- Amy-Jo Casbon, PhD - Director, Research & Operation
- John Joly, PhD - CMC Advisor
- Allen Ebens, PhD - Strategic Advisor
- Headquarters:
- Redwood City, USA
- Shenzhen, China
- Number of Employees: No information is available.
- Revenue: No information is available.
- Known For: Pioneering innovative therapies in oncology and autoimmune diseases through a novel Myeloid Engager Platform.
Products
Myeloid Engager Platform
- High-Level Description:
- A proprietary, versatile, fully humanized bispecific antibody platform. Designed to leverage the power of myeloid cells, particularly macrophages, to create effective therapies for cancer and autoimmune diseases.
- Key Features:
- Activates innate receptors on myeloid cells following engagement with target-associated antigens (TAA) leading to phagocytosis and depletion of target cells.
- Minimal proinflammatory cytokine release ensures safety.
- Universal platform causing potent phagocytic killing of distinct target cells expressing TAAs.
- Enhanced Fc receptor function resulting in dual activation of both myeloid and NK cells.
- Engineered to increase stability, antibody titer, and reduce structural heterogeneity.
- Mechanisms include activation of phagocytosis, ADCC (via NK cells), and reprogramming of myeloid cells to enhance immune response.
Recent Developments
- New Products Launched:
- LTZ-301: A myeloid engager immunotherapy for treating relapsed or refractory non-Hodgkin lymphoma (r/r NHL). The IND application was cleared by the FDA in February 2025, allowing trial initiation.
- Financing Milestones:
- July 2024: Over $20 million Series A Financing for development of its Myeloid Engager-Based Immunotherapy Pipeline.
- May 2023: Over $10 million Pre-A+ Financing to advance the development of its immunotherapy pipeline.
- April 2022: Secured $17 million Pre-Series A financing for immunotherapy development.
- Partnerships and Other Developments:
- The company was launched by former executives from Genentech, suggesting a strong foundational backing in biotech expertise.
No further information is available for new partnerships or additional features added to existing products.
